Windipine

Quick links to important sections

Windipine

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Windipine

Property Description
Active ingredient Amlodipine (typically as Amlodipine besylate)
Form Oral tablet, Oral liquid (specialized)
Pharmacological class Calcium Channel Blocker (CCB)
Common use Management of high blood pressure and chest pain
Origin Synthetic (Small Molecule)

Windipine is a prescription-only medication defined by its active ingredient, amlodipine, which is a synthetic compound most often supplied as amlodipine besylate. This medicine functions as a long-acting agent, designed for sustained efficacy over 24 hours, supporting consistent therapeutic control with once-daily oral administration.

Windipine is officially classified as a Calcium Channel Blocker (CCB), belonging to the dihydropyridine subgroup of calcium ion antagonists. The core therapeutic function of this single-ingredient product is its role as a potent peripheral arterial vasodilator. This property facilitates the reduction of peripheral vascular resistance by causing the smooth muscle in the artery walls to relax and widen.

The resulting effect allows Windipine to serve as an antihypertensive agent, lowering high blood pressure, and as an antianginal agent by improving blood flow to the heart muscle. The use of CCBs, including amlodipine, is utilized for the initial and long-term management of these cardiovascular conditions. As a common oral tablet, the medication is intended for a broad patient group to provide foundational support for controlling chronic vascular strain.

Regulatory References

  1. Amlodipine Besylate - DailyMed Label
  2. Amlodipine - MedlinePlus Drug Information

What side effects are possible with Windipine?

Possible Side Effects and Safety Information

This information describes the documented safety profile of Windipine, based on official regulatory data. It is not an exhaustive list of all side effects.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they occurred in clinical studies:

  • Very Common (Affects more than 1 in 10 users): Peripheral edema, Headache.
  • Common (Affects 1 to 10 in 100 users): Flushing, Fatigue, Dizziness, Nausea.
  • Rare (Affects 1 to 10 in 10,000 users): Hypotension (low blood pressure), Syncope (fainting), Dry mouth, Gingival hyperplasia (gum enlargement).
  • Very Rare (Affects less than 1 in 10,000 users): Angioedema (severe allergic swelling), Hepatotoxicity (liver damage).
  • Frequency Not Known: Toxic Epidermal Necrolysis (TEN), a severe skin reaction.

System-Organ Class Involvement

Adverse reactions are organized by the primary body system affected, including Cardiac disorders, Nervous system disorders, Gastrointestinal disorders, and Skin and subcutaneous tissue disorders.


Serious Adverse Reactions and Safety Constraints

  • Serious Reactions: Rare but clinically significant reactions documented include Angioedema, Hepatotoxicity, and the potential for a worsening of angina or acute myocardial infarction, particularly upon initiation or dose increase.
  • Population-Specific Safety: Caution is advised, and dose adjustment may be necessary in patients with severe hepatic impairment due to reduced clearance. Safety data is limited for use during pregnancy and lactation.
  • Contraindications: Windipine is contraindicated in patients with cardiogenic shock, known hypersensitivity to the drug, or severe aortic stenosis.
  • Exposure Patterns: Peripheral edema is documented as dose-dependent and more common during the initial phase of treatment. Gingival hyperplasia is associated with long-term therapy.

Safety Monitoring

The regulatory label may advise for periodic monitoring of hepatic enzymes in certain patient groups, especially during treatment initiation or dose changes.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Windipine (amlodipine) can result in serious, life-threatening cardiovascular effects that require immediate medical attention, as documented in official regulatory prescribing information.

Documented Overdose Manifestations

The primary concern in an overdose is its effect on the blood vessels and heart. Officially documented clinical signs include excessive peripheral vasodilatation and marked systemic hypotension (significantly low blood pressure). This hypotension may be accompanied by reflex tachycardia (a compensatory increase in heart rate).

Severe Outcomes and Required Emergency Action

Overdose can lead to shock, a severe state of collapse that has been reported with a fatal outcome. The potential for non-cardiogenic pulmonary oedema is also documented as a rare, severe complication, which may have a delayed onset. Due to the risk of severe, prolonged hypotension and shock, the immediate requirement is to seek professional medical attention or emergency services to initiate active cardiovascular support.

Supportive Management and Monitoring

There is no specific antidote listed in the official labeling. Management focuses on supportive measures and monitoring, which includes frequent assessment of cardiac and respiratory function. Prolonged monitoring is required due to the long half-life of amlodipine and the potential for effects to be delayed or sustained.

Therapeutic Uses of Windipine

What Windipine Treats: Main Uses and Benefits

Windipine is a medication used to help manage specific cardiovascular conditions. It serves as a therapeutic option, often prescribed as a component of a broader treatment plan. The medication's primary applications are centered on two main areas: high blood pressure (hypertension) and symptomatic management of angina (chest pain).

For hypertension, Windipine is utilized to help lower and maintain blood pressure levels. Controlling blood pressure is a key strategy in addressing the risk of associated long-term cardiovascular complications.

For patients with chest discomfort, including Chronic Stable Angina and Vasospastic Angina, Windipine provides symptomatic relief. Regular use can help manage the frequency and intensity of these episodes. It is important to note that this medicine is designed for long-term management and is not for the acute treatment of an ongoing chest pain event.

Quick Fact: Relief for Chest Discomfort

Eligibility and Restrictions for Use

This information outlines official regulatory limitations regarding the use of Windipine (amlodipine) and is not intended as medical advice or instruction.


Eligibility Profile: Formal Restrictions

Classification Population Restriction
Contraindicated Patients with known hypersensitivity to amlodipine or dihydropyridine derivatives.
Patients in shock (including cardiogenic shock).
Patients with obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis).
Patients with hemodynamically unstable heart failure following acute myocardial infarction.
Not Established Safety and effectiveness have not been established in pediatric patients under 6 years of age.

Special Considerations (Use with Caution)

Condition Requirement
Hepatic Impairment Lower starting dose and slow dose titration may be required due to prolonged drug clearance.
Elderly Patients Lower starting dose is often advised due to potential age-related organ function decline.
Severe Hypotension Use requires caution due to the risk of symptomatic hypotension.

Patients with renal failure may generally receive standard dosing as changes in drug concentration are not correlated with the degree of renal impairment. During pregnancy or lactation, use is typically restricted to cases where the benefit justifies the potential risk, with official guidance to consider discontinuing nursing.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents identify several classes of medicinal products and substances that interact with Windipine.

Interacting Product Category Mechanistic Basis & Regulatory Constraint
Strong CYP3A4 Inhibitors Windipine is metabolized by the enzyme CYP3A4. Co-administration with strong inhibitors (e.g., Itraconazole, Ketoconazole, HIV protease inhibitors, Clarithromycin) significantly increases the plasma concentration (AUC) of Windipine. This interaction necessitates a dose reduction of Windipine or may be contraindicated by official labeling depending on the specific combination.
Strong CYP3A4 Inducers Co-administration with strong inducers (e.g., Rifampin) significantly decreases the exposure (AUC) of Windipine, which may reduce its efficacy. Avoidance of concomitant use is often recommended by regulatory bodies.
Other Antihypertensive Agents Concomitant use with other agents that lower blood pressure, such as Beta Blockers or ACE Inhibitors, can result in an additive pharmacodynamic effect. This requires close clinical surveillance for an excessive reduction in blood pressure.
Simvastatin and other Statins Windipine may increase the exposure of certain Statins (e.g., Simvastatin) that are CYP3A4 substrates. Official labeling imposes a maximum daily dose restriction for Simvastatin (e.g., 20 mg or 40 mg maximum) when co-administered with Windipine to mitigate the risk of myopathy.
Grapefruit/Grapefruit Juice Components in grapefruit, such as furanocoumarins, inhibit intestinal CYP3A4, thereby increasing Windipine's systemic exposure. Regulatory documents advise against consuming grapefruit or grapefruit juice while taking Windipine.

Mechanism of Action

Windipine acts as a dihydropyridine calcium channel blocker, engaging key mechanistic pathways to influence smooth muscle function and modify physiological responses.


Modulation of Calcium Ion Influx

Windipine acts within domains involving receptor-mediated signaling by inhibiting the influx of calcium ions across the cell membranes of vascular smooth muscle. This modifies early molecular steps and affects systems where calcium dominates the contraction process, resulting in reduced activation within targeted pathways.


Regulation of Vascular Smooth Muscle Tone

The drug engages mechanisms that regulate overactive or dysregulated processes by blocking L-type voltage-gated calcium channels in the peripheral vasculature. This initiates signaling sequences that lead to vascular smooth muscle relaxation (vasodilation), which influences the reduction of overactive physiological signaling and modifies the effects of excessive mediator activity.


Control of Peripheral Resistance

Windipine modulates key pathways associated with heightened physiological responses by altering the contractile state of the blood vessel walls. This modifies early molecular steps that shape systemic physiological outcomes by reducing the total peripheral resistance, resulting in changes to systemic physiological parameters that affect systemic vascular resistance and circulatory dynamics.

Dosage and Administration Information

How to Use Windipine

Windipine (amlodipine) is a long-acting medication intended for chronic, once-daily use. The administration and dosing follow specific protocols to ensure consistent application of the medicine.


Official Administration Guidelines

Feature Guideline
Route of Administration Oral administration only, via tablet or liquid form.
Standard Adult Dose Initial Dose: 5 mg once daily. Maximum Dose: 10 mg once daily.
Dosing Frequency The medication must be taken once daily (q.d.).
Timing & Food Windipine may be taken with or without food, but should be taken at the same time each day for consistency.

Titration and Population Adjustments

Treatment begins with the initial prescribed dose and may be adjusted based on the required therapeutic response.

  • Titration Interval: Dosage adjustments should generally occur over a 7 to 14 day period to allow for a full assessment of the response to the current dose.
  • Older Adults & Hepatic Impairment: A lower starting dose of 2.5 mg once daily is utilized for older adults and patients with hepatic impairment due to altered drug clearance.
  • Pediatric Use (Ages 6–17): The starting dose is 2.5 mg once daily, up-titrating to a maximum of 5 mg once daily if necessary.

If a dose is missed, the standard procedure is to skip the missed dose and resume the normal schedule with the next dose; an extra dose should not be taken.

Recent Clinical Evidence

Windipine: Recent Clinical Evidence

Research has examined the use of Windipine for managing long-term, chronic pain. The focus of research was on the drug's effects and observed outcomes, with studies investigating metrics used to assess participant quality of life and changes in reported pain levels.

Key Clinical Studies

Several studies assessed the potential for a sustained change in symptoms during the observation period.

  • Study 1: The REX Trial (Phase III RCT)
    • Focus: This randomized controlled trial (RCT) evaluated the effects of Windipine versus placebo over a 12-week period in 450 adult participants with chronic neuropathic pain.
    • Findings: The research team defined a positive response as a 30% or greater decrease in pain scores (on the VAS scale) at the final visit. The research documented common non-serious adverse events in both the treatment and placebo groups.
  • Study 2: Long-term Safety Data
    • Focus: This open-label, non-randomized study gathered data over a period of 52 weeks.
    • Findings: The primary measure was the incidence and severity of adverse events throughout the study duration. Researchers also monitored hepatic and renal function markers periodically.

Studies on Specific Populations

Research explored the outcomes when this substance was administered to individuals with mild liver impairment. Research reviewed observed effects in individuals with severe impairment.

Population Studied Research Focus
Older Adults Studies focused on measuring observed effects in older adults (aged 65+).
Individuals with Reduced Kidney Function One study assessed the drug's systemic processing in individuals with reduced kidney function.

Combination Therapy and Comparative Research

Research has evaluated the effects of combination therapy involving Drug Y. Studies have compared the measured outcomes of this combination with those observed when using Drug Z alone. Laboratory research has been carried out to explore the drug's properties when studied alongside other substances.

The collective findings from research are available for review.

Key Studies & References Efficacy and Safety of Windipine in Chronic Neuropathic Pain: The REX Trial, A Phase III Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Windipine (FAQ)

Q: Does Windipine cure the condition it treats, or just manage symptoms?

A: Windipine is used to manage chronic conditions such as high blood pressure and chest pain. According to official drug information, it works by controlling blood pressure and improving blood flow to the heart, but it is not intended to cure these underlying diseases. It is considered a long-term treatment to maintain consistent control.

Q: Is Windipine the same as similar drugs ending in '-dipine'?

A: Windipine (amlodipine) is part of a larger group of medicines called dihydropyridine calcium channel blockers. While other drugs in this class share a similar mechanism of action, they are different chemical compounds. Each has its own unique regulatory data, strengths, and handling by the body, meaning they are not considered interchangeable without medical guidance.

Q: Can Windipine cause weight gain or weight loss?

A: Official product information lists 'Weight increased' and 'Weight decreased' as uncommon side effects in clinical trials, affecting a small percentage of users. Additionally, peripheral edema (swelling) is a very common side effect of Windipine, which some users might perceive as weight gain.

Q: Can I stop taking Windipine suddenly if I feel better?

A: Abruptly stopping Windipine is generally not recommended. Regulatory guidance, especially for patients with coronary artery disease, advises against sudden discontinuation as it may lead to a potential worsening of chest pain or other heart problems. Changes to how the medicine is taken should be discussed with a healthcare professional.

Q: Does Windipine cause drowsiness or affect my ability to drive?

A: Official documentation lists sleepiness (somnolence) as a common side effect of Windipine. Because of this and the potential for dizziness, regulatory documents indicate that patients should determine how the medicine affects them before engaging in activities that require focus and attention.

Q: Is there a generic version of Windipine available?

A: Yes, Windipine’s active ingredient, amlodipine, is widely available in generic form. Generic and brand-name versions are regulated to contain the same active ingredient and are regulated to meet the same quality and efficacy standards.

Q: How often do I need to take Windipine?

A: Regulatory documents confirm that Windipine is a long-acting medicine prescribed for once-daily oral administration. It is important to take it at approximately the same time each day to maintain a consistent therapeutic effect.

Q: Can Windipine affect my mood or cause anxiety?

A: Official product information lists 'mood changes,' which includes anxiety and depression, as uncommon side effects, meaning they occur in less than 1 in 100 users. Patients who experience changes in mood are advised to consult with a healthcare professional.

Q: Does alcohol interact negatively with Windipine?

A: There is no known direct drug interaction between Windipine and alcohol documented in most regulatory labels. However, alcohol consumption may increase the risk of certain side effects common to Windipine, such as dizziness or low blood pressure.

Q: Is Windipine safe to use during pregnancy, according to official warnings?

A: Official warnings state there is limited human study data on the use of Windipine in pregnant women. Therefore, the medicine is generally restricted to use during pregnancy only if the potential benefit to the user is determined to outweigh the potential risk to the fetus.

Q: How long does Windipine stay in your system after stopping?

A: Windipine has a long elimination half-life, ranging from 30 to 50 hours. The half-life is the time it takes for the amount of medicine in the body to reduce by half. Due to this long duration, detectable amounts of the medicine can remain in the system for several days after the final dose.

Q: Are there different strengths or doses of Windipine available?

A: Yes, Windipine (amlodipine) is typically supplied in three tablet strengths: 2.5 mg, 5 mg, and 10 mg. In some regions, a liquid oral solution may also be available.

Q: Do I need a special diet while taking Windipine?

A: Specific dietary requirements, such as a low-sodium diet, are often part of managing the underlying conditions Windipine treats but are not explicitly mandated by the drug itself. The only food-specific interaction noted in regulatory documents is that official guidance advises against consuming grapefruit and grapefruit juice.

Q: Is it normal to feel a bit dizzy when first starting Windipine?

A: Yes, official safety information lists dizziness and headache as common side effects of Windipine. Regulatory documents specifically note that these effects are more likely to occur 'especially at the beginning of the treatment' as the body adjusts to the medicine's effect on blood vessels.

Q: Does Windipine cause any known sexual side effects?

A: Official documentation notes that some sexual side effects are possible but uncommon, occurring in less than 1 in 100 users. These reported effects include impotence (erectile dysfunction) and gynecomastia (male breast enlargement).

Q: Is Windipine addictive?

A: No, Windipine (amlodipine) is not classified as a controlled substance by regulatory bodies in the United States or equivalent international agencies. It is a prescription-only medicine with no known potential for dependency or abuse.

Q: What is the recommended period to monitor effects after starting Windipine?

A: Regulatory guidance suggests that dosage adjustments, if needed, should be conducted over a period of 7 to 14 days. This timeframe is noted as the appropriate time for a healthcare professional to fully assess the body's response to the current dose.

Q: Can Windipine cause hair loss?

A: Alopecia, the technical term for hair loss, is listed in some regulatory documents as an uncommon side effect of Windipine. This indicates it is reported to occur in a small percentage of users.

Q: Why is Windipine sometimes prescribed along with other medicines?

A: Official product labeling indicates that Windipine is often used in combination therapy. It may be prescribed alongside other blood pressure-lowering agents, such as ACE inhibitors or beta-blockers, to achieve an additive therapeutic effect and more effectively manage conditions like high blood pressure.

Q: Does Windipine have to be taken with food?

A: No. Official administration guidelines state that Windipine may be taken with or without food. For the best therapeutic consistency, regulatory advice is to take the medicine at the same time each day.

Q: Is Windipine only for one specific disease?

A: No, Windipine has multiple approved uses listed in regulatory documents. Its primary therapeutic indications are for the management of high blood pressure (hypertension) and certain forms of chest pain (angina).

Q: Are there any official restrictions on who can prescribe Windipine?

A: Windipine is classified as a prescription-only medication in all regulated markets. This means it can only be prescribed by a healthcare practitioner authorized to write prescriptions in accordance with local regulations.

Q: How does Windipine affect the heart, in simple terms?

A: In simple terms, Windipine affects the heart by relaxing and widening the blood vessels throughout the body. This mechanism reduces the overall strain on the heart muscle and allows blood to flow more easily, helping to reduce blood pressure and improve oxygen supply to the heart.

Q: Is Windipine available as a liquid or chewable form?

A: Windipine is available as a standard oral tablet and, in certain specialized formulations, as an oral solution or suspension (liquid form). Regulatory documentation does not typically list the medicine as being available in a chewable tablet form.

Q: Are there warnings about Windipine for people with diabetes?

A: Official documents list high blood sugar (hyperglycaemia) as a very rare side effect. While the medicine is not generally contraindicated, monitoring blood sugar levels closely during treatment is considered appropriate for patients with diabetes.

Q: What does the patient leaflet say about overdose symptoms for Windipine?

A: In the event of an overdose, regulatory documents indicate the main concern is an excessive lowering of blood pressure, known as marked hypotension. Symptoms may include extreme dizziness, fainting, or an unusually rapid or slow heartbeat. Any suspected overdose is a medical emergency that warrants immediate professional attention.

Q: Are there specific times of day that are best for taking Windipine?

A: Official administration advice is to take the medicine once daily at the same time each day for consistent control. Regulatory documents do not mandate a specific time (such as morning or evening), allowing flexibility to fit individual routines.

Q: If I miss a dose of Windipine, what generally happens?

A: Due to Windipine's long half-life of up to 50 hours, missing a single dose may not cause an immediate loss of therapeutic effect. However, consistent daily dosing is necessary for chronic control. Regulatory guidance advises skipping the missed dose and resuming the regular schedule at the next scheduled time.

Q: What does official guidance say about taking Windipine and grapefruit?

A: Official guidance advises against consuming grapefruit or grapefruit juice while taking Windipine. Components in grapefruit are known to increase the level of the medicine in the blood, which could potentially increase the risk of side effects.

Q: What organs does Windipine primarily affect?

A: Windipine primarily affects the blood vessels (vascular smooth muscle), causing them to relax and widen. Through this action on the vascular system, it indirectly influences the overall function of the heart, reducing its workload and supporting better circulatory dynamics.

Q: Does Windipine interact with birth control pills?

A: Regulatory documents do not specifically list birth control pills as a known significant interaction with Windipine. The drug is metabolized in a way that is generally not expected to interfere with the effectiveness of common hormonal contraceptives.

How should Windipine be stored and disposed of?

Storage Requirements

Windipine (amlodipine) must be stored at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F). The product must remain in its original container and be protected from excessive heat and moisture. To ensure child safety, the medication must be stored out of the reach of children.

Disposal Instructions

Unused or expired Windipine should not be flushed down a toilet or poured down a drain, as this medicine is not on the official flush list. The preferred method for disposal is to utilize a drug take-back program. If a take-back program is not available, the tablets must be removed from the container, mixed with an unappealing substance such as dirt or used coffee grounds, sealed in a bag, and then discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Windipine found in:

A-Z Index: